Cytomegalovirus immune globulin - Kamada
Alternative Names: CMV-IGIV; CytoGam; Cytomegalovirus immune globulin intravenous - KamadaLatest Information Update: 05 Nov 2023
At a glance
- Originator MedImmune
- Developer Saol Therapeutics
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cytomegalovirus infections
Most Recent Events
- 31 Dec 2022 Cytomegalovirus immune globulin is available on a Named Patient Access Programme for the treatment of Cytomegalovirus infections in Qatar
- 22 Nov 2021 Kamada acquires cytomegalovirus immune globulin from Saol Therapeutics
- 30 Apr 2012 CSL initiates enrolment in a phase III trial for Cytomegalovirus infections (prevention of congenital CMV) in the US (NCT01376778)